Nick Goeden
About Nick Goeden
Nick Goeden: Founder and Chief Technology Officer
Nick Goeden serves as the Founder and Chief Technology Officer of Capsida, a company focused on gene therapy. His leadership and vision have been instrumental in driving the company's translational approach to developing advanced therapies. As Chief Technology Officer, he oversees the technological and strategic aspects of the company's initiatives, ensuring the development and implementation of cutting-edge solutions.
Nick Goeden's Postdoctoral Research at Caltech
Nick Goeden conducted postdoctoral research in the laboratory of Dr. Viviana Gradinaru at the California Institute of Technology (Caltech). During his tenure in the Gradinaru lab, Goeden collaborated with experts in the field of gene therapy, contributing to significant advancements in AAV technology. His research work at Caltech laid the foundation for his later initiatives in gene therapy.
Nick Goeden's Collaboration with Nicholas Flytzanis
While working in Dr. Viviana Gradinaru's lab at Caltech, Nick Goeden met Nicholas Flytzanis, who was then a Ph.D. student. The two researchers co-envisioned a translational focus for the AAV gene therapy platform. This meeting of minds and shared vision played a crucial role in the conceptualization and eventual founding of Capsida.
Founding of Capsida and Translational Gene Therapy Focus
The concept for Capsida was sparked when Nick Goeden approached Dr. Viviana Gradinaru with an idea for a gene therapy company. This pivotal discussion took place over lunch at a restaurant named Nick's. Goeden's innovative approach and conceptual vision for a translational focus on AAV gene therapy paved the way for the establishment of Capsida, aimed at addressing unmet medical needs through advanced gene therapy solutions.